Welcome to our dedicated page for Evotec SEC filings (Ticker: EVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles Evotec SE (EVO) filings with the U.S. Securities and Exchange Commission, giving investors structured access to the company’s regulatory disclosures. As a foreign private issuer, Evotec files its annual report on Form 20-F and submits interim information and material updates on Form 6-K.
Recent Form 6-K submissions referenced in the company’s disclosures include reports on financial results for the first half and first nine months of 2025, adjustments to revenue guidance while confirming profit guidance, and details of a share repurchase program. Other 6-Ks transmit press releases on strategic transactions, such as the planned and then finalized agreements with Sandoz regarding the Just - Evotec Biologics Toulouse site and an indefinite license to Evotec’s continuous manufacturing platform technology.
Additional 6-K filings cover business updates on Evotec’s strategy for sustainable and profitable growth, including the renaming of its Shared R&D segment to Discovery & Preclinical Development, progress in collaborations with Bristol Myers Squibb and Bayer, and the evolution of Just - Evotec Biologics toward an asset-lighter, technology-centric model.
Through Stock Titan, users can review these SEC documents alongside AI-powered summaries that clarify key points from lengthy filings. This includes context on revenue mix, cost initiatives, strategic partnerships, and capital allocation measures such as buybacks. For deeper analysis, investors can focus on how Evotec describes its platform technologies, partnered R&D asset portfolio, and guidance for future periods within its official filings.
Evotec SE reports that its Chief Financial Officer Paul Hitchin will step down on April 30, 2026 for personal reasons described as unrelated to the company. Hitchin, who has served as CFO since March 1, 2025, is credited with guiding Evotec through a significant financial and strategic evolution and supporting a broader company transformation.
Claire Hinshelwood has been appointed as the new CFO effective May 1, 2026. She brings more than 30 years of financial leadership experience, including roles as Group Chief Finance Officer of BMI Group, Global Head of Finance Operations at Novartis, and senior finance roles at Syngenta. Evotec’s CEO and both CFOs emphasize continuity in executing the company’s transformation plan aimed at increased profitability, sustainable growth, and value creation.
Evotec SE reported fourth quarter and full-year 2025 results showing stronger profitability despite slightly lower annual revenue. Q4 Group revenues were €253.3 million, up 14% year-on-year, while adjusted Group EBITDA more than doubled to €58.0 million, helped by a license payment under the Sandoz agreement.
For full-year 2025, Group revenues were €788.4 million, a modest 1.1% decline, but adjusted Group EBITDA rose to €41.1 million from €22.6 million as cost discipline delivered structural savings of €60 million. Liquidity at year-end stood at €476 million, reflecting a net cash position.
Segment trends diverged: Drug Discovery & Preclinical Development revenues fell 13.5% to €528.9 million with negative adjusted EBITDA, while Just – Evotec Biologics revenues grew 39% to €259.4 million and adjusted EBITDA rose to €53.2 million, supported by the Sandoz transaction valued at more than $650 million. The company launched its Horizon operating model to streamline sites, create Centers of Excellence and target about €75 million of structural cost savings by the end of 2027.
Evotec outlines its 2025 business, risk profile, and strategic shift toward a more asset‑light, profitability‑focused model. The company operates under IFRS, is listed on Nasdaq via ADSs, and had 177,778,907 ordinary shares outstanding as of December 31, 2025.
Evotec runs two main segments: Just – Evotec Biologics, which provided 33% of 2025 third‑party revenues, and Discovery & Preclinical Development, which contributed 67%. As of December 31, 2025, it held €476.4 million in cash, cash equivalents and investments, supported by an upfront $350 million payment from the sale of Just – Evotec Biologics EU SAS to Sandoz and use of a €44 million EIB loan tranche.
The company highlights extensive risk factors, including macroeconomic pressures, customer concentration, execution risks from its “Project Horizon” transformation, regulatory and ESG compliance burdens, IP and litigation exposure, cyber and data protection risks, and identified material weaknesses in internal control over financial reporting as of December 31, 2025.
Evotec SE reported two key developments. The company expects to receive approximately $100 million in upfront consideration, plus up to about $58 million in contingent consideration, from the sale of its 3.14% equity stake in Tubulis GmbH as part of Tubulis’ acquisition by Gilead Sciences, with closing expected in the second quarter of 2026.
Evotec also announced that its Supervisory Board has proposed Dieter Weinand as Chairman of the Supervisory Board, to be elected at the Annual General Meeting on June 11, 2026, succeeding Prof. Dr. Iris Löw-Friedrich as part of a planned succession process.
Evotec SE received an amended ownership filing from investment entities affiliated with MAK Capital. MAK Capital Fund, MAK Capital One L.L.C. and Michael A. Kaufman report beneficial ownership of 12,503,512 Ordinary Shares, representing 7.0% of Evotec’s Ordinary Shares based on 177,877,782 shares outstanding as of March 30, 2026.
This Amendment No. 1 updates a prior Schedule 13D and notes that the reporting persons sent an April 2 letter to Evotec’s Supervisory and Management Board, filed as an exhibit, in furtherance of their stated purpose for holding the stake.
Evotec SE received an activist disclosure from MAK Capital, which reported beneficial ownership of 12,503,512 ordinary shares, or about 7.0% of Evotec’s outstanding shares as of March 30, 2026. MAK Fund acquired these shares in open-market purchases for approximately 72,334,719 euros, funded with working capital.
MAK has begun actively engaging Evotec’s leadership. It spoke with the Chairwoman of the Supervisory Board to advocate for strategic and governance changes aimed at enhancing long-term shareholder value. MAK asked Evotec to consider nominating Dr. Wolfgang Hofmann to the Supervisory Board and to pursue an IPO followed by a spin-out of the Just-Evotec Biologics US subsidiary. No agreements have been reached, but MAK intends to continue its engagement.
Evotec launched “Horizon”, the next phase of its multi‑year transformation, introducing a new operating model across operations, science and commercial execution. The company plans to streamline its global footprint to 10 sites and adjust its workforce by up to 800 positions over the next two years.
Structural Horizon measures are expected to deliver approximately €75 million run‑rate cost savings by the end of 2027, against total cash restructuring charges of about €100 million over 2026–2028, plus non‑cash impairments. Evotec enters 2026 with around €60 million annualized cost savings already realized in 2025.
Preliminary unaudited 2025 figures indicate group revenues of about €788 million and adjusted Group EBITDA of roughly €41 million, within prior guidance. For 2026, Evotec guides to group revenues of approximately €700–780 million and adjusted Group EBITDA of about €0–40 million.
The Just – Evotec Biologics segment is expected to post around €259 million revenues, up 40% year on year, and about €53 million adjusted EBITDA, while the Discovery & Preclinical Development segment is expected at roughly €529 million revenues, down 13%, with adjusted EBITDA of about -€12 million.
For 2026–2030, Evotec’s framework targets group revenues above €1 billion (8–12% CAGR) and an adjusted EBITDA margin reaching 20% by 2028 and exceeding that level by 2030.
Novo Holdings A/S now reports no ownership in Evotec SE. In this amended Schedule 13G/A, the Danish investment firm states it beneficially owns 0 ordinary shares of Evotec SE, representing 0.0% of the class, as of 12/31/2025.
The filing shows Novo Holdings has no sole or shared voting power and no sole or shared dispositive power over any Evotec shares. It confirms that Novo Holdings’ holdings are now 5 percent or less of the class, meaning it is no longer a significant beneficial owner under U.S. disclosure rules.
Evotec SE received a Schedule 13G filing from investment entities associated with MAK Capital, disclosing a significant passive ownership position. MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman together report beneficial ownership of 9,386,434 Ordinary Shares, representing 5.3% of Evotec’s Ordinary Shares outstanding as of January 9, 2026, based on the issuer’s website disclosure of 177,778,907 shares. The reporting persons indicate they hold shared power to vote and dispose of these shares and certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Evotec SE.
Evotec SE filed a Form 6-K noting that on January 16, 2026 it submitted several Notifications of Major Holdings to the German financial regulator, Bundesanstalt für Finanzdienstleistungsaufsicht. These notifications, which disclose significant shareholdings under German law, are attached as Exhibits 99.1, 99.2 and 99.3. Exhibit 99.1 and 99.2 relate to notifications identified with “GS” dated January 13, 2026 and January 9, 2026, respectively, and Exhibit 99.3 relates to a notification identified with “MAK” dated January 9, 2026. The report is signed on behalf of Evotec SE by Chief Executive Officer Christian Wojczewski.